
- ONCOLOGY Vol 20 No 4
- Volume 20
- Issue 4
Study Shows MRI Can Detect Breast Disease Missed by Mammography
Researchers have found that mammography coupled with magnetic resonance imaging (MRI) is extremely sensitive in the detection of ductal carcinoma in situ (DCIS).
Researchers have found that mammography coupled with magnetic resonance imaging (MRI) is extremely sensitive in the detection of ductal carcinoma in situ (DCIS). The recent study, which was published in The Breast Journal (11[6]:382-390, 2005), examined the medical records of women diagnosed with DCIS, aged 34 to 79 years, who underwent MRI and mammographic examinations over approximately 2 years.
The results revealed 39 sites of pure DCIS in 33 breasts of 32 women. In each of these women, both MRI and mammograms were performed prior to surgery. Of the 33 breasts involved, DCIS was detected by MRI alone in 64%, and detected by mammography alone in only 3%. MRI and mammography together detected DCIS in 24% of breasts; in 9%, DCIS was found at mastectomy but the mammogram and MRI were negative. The nuclear grade of DCIS detected by MRI and mammography was similar, although the size of lesions identified by MRI was larger. Breast density did not affect the results.
Recommendations
"The results from our small, select group of patients suggest that in women with known or suspected DCIS, determination of the presence and extent of disease may be best established with mammography complemented by MRI," concluded the researchers, led by Jennifer Menell, md, Memorial Sloan-Kettering Cancer Center.
The American Cancer Society recommends that women age 40 and older should have a mammogram every year and that those at increased risk should talk with their doctors about the benefits and limitations of starting mammograms when they are younger, having additional tests (such as MRI), or having more frequent exams.
Articles in this issue
over 19 years ago
Handbook of Brain Tumor Chemotherapyover 19 years ago
Budget Plan Cuts NCI Spending by 0.8% for Fiscal Year 2007over 19 years ago
FDA Guidances for Early Human Testing of New Drugsover 19 years ago
Prostate Treatment Decisions Based on Perception More Than Factover 19 years ago
FDA Approves Cetuximab to Treat Head and Neck Cancerover 19 years ago
The FDA and the Person With Cancer: Give PROs a Chanceover 19 years ago
Poverty Trumps Race to Explain Poor Prostate Cancer Outcomesover 19 years ago
AJN Releases Report on Care for Long-Term Cancer SurvivorsNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.



















































































